HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
92pdX50g86z2nSJG